Terns Pharmaceuticals Highlights New Preclinical Data For TERN-601 Program In Obesity At The ADA's 83rd Annual Scientific Session And Upcoming Events
Portfolio Pulse from Happy Mohamed
Terns Pharmaceuticals announced new preclinical data for its TERN-601 program in obesity, showing significant improvements in glucose tolerance, food intake suppression, and gastric emptying in a transgenic mouse model. The company plans to initiate a Phase 1 clinical trial in the second half of this year, with top-line data expected in 2024.
June 26, 2023 | 8:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Terns Pharmaceuticals' TERN-601 program demonstrated positive preclinical results in obesity treatment, with a Phase 1 clinical trial planned for H2 2023.
The positive preclinical data for TERN-601 indicates that the program has potential in treating obesity. As the company moves forward with a Phase 1 clinical trial, investor interest in Terns Pharmaceuticals may increase, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100